Literature DB >> 6271933

Reoperation for glioblastoma.

B Young, E H Oldfield, W R Markesbery, D Haack, P A Tibbs, P McCombs, H W Chin, Y Maruyama, W F Meacham.   

Abstract

The results of a second operation for tumor removal in 24 adult patients with supratentorial glioblastoma multiforme or anaplastic astrocytoma were analyzed. The median survival time after reoperation was 14 weeks. Five of the 24 patients lived 6 months or longer after reoperation. Only three of these patients maintained a Karnofsky rating (KR) of at least 60 for 6 months or longer after reoperation. Preoperative neurological status (KR) is the most significant determinant of survival after reoperation (p = 0.02). When the KR is at least 60, median survival after reoperation is 22 weeks. When the KR prior to reoperation is less than 60, median survival is 9 weeks. Only one of 13 patients with a KR of less than 60 prior to reoperation survived longer than 6 months after the second operation. The interval between first and second operation is significantly related to survival (p = 0.03), but when adjustment is made for the KR the interoperative interval is no longer significantly related to survival after the second operation (p = 0.39). Age, sex, and location of tumor were not significantly related to duration of survival. This study suggests that reoperation is most likely to produce the best result when the KR is at least 60 and the interval between operations is longer than 6 months. Using these criteria, one-third of the patients could be expected to survive with a KR of at least 60 for 6 months. The study indicates that reoperation should not be carried out when the KR is less than 60.

Entities:  

Mesh:

Year:  1981        PMID: 6271933     DOI: 10.3171/jns.1981.55.6.0917

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  23 in total

Review 1.  Historical development of surgery for glial tumors.

Authors:  M Salcman
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

2.  Glioblastoma--the consequences of advanced patient age on treatment and survival.

Authors:  Andreas M Stark; Jürgen Hedderich; Janka Held-Feindt; H Maximilian Mehdorn
Journal:  Neurosurg Rev       Date:  2006-11-21       Impact factor: 3.042

3.  Treatment of malignant recurrent glioma by intra-arterial, infra-ophthalmic infusion of HECNU 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl) urea. A phase II study.

Authors:  M Poisson; J Chiras; F Fauchon; C Debussche; J Y Delattre
Journal:  J Neurooncol       Date:  1990-06       Impact factor: 4.130

4.  Should we reoperate for recurrent high-grade astrocytoma?

Authors:  Jin-fang Xu; Jun Fang; Yi Shen; Jian-min Zhang; Wei-guo Liu; Hong Shen
Journal:  J Neurooncol       Date:  2011-05-17       Impact factor: 4.130

5.  High dose chemotherapy with autologous stem cell rescue in adults with malignant primary brain tumors.

Authors:  L E Abrey; M K Rosenblum; E Papadopoulos; B H Childs; J L Finlay
Journal:  J Neurooncol       Date:  1999-09       Impact factor: 4.130

6.  Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study.

Authors:  Alysson Wann; Patrick A Tully; Elizabeth H Barnes; Zarnie Lwin; Rosalind Jeffree; Katharine J Drummond; Hui Gan; Mustafa Khasraw
Journal:  J Neurooncol       Date:  2018-01-02       Impact factor: 4.130

7.  Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA.

Authors:  E W Jeffes; Y B Beamer; S Jacques; R S Silberman; B Vayuvegula; S Gupta; J S Coss; R S Yamamoto; G A Granger
Journal:  J Neurooncol       Date:  1993-02       Impact factor: 4.130

8.  Glioblastoma revisited: do clinical observations match basic science theory? Radiosurgery: clinical observations.

Authors:  E Alexander
Journal:  J Neurooncol       Date:  1993-08       Impact factor: 4.130

9.  Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma.

Authors:  Graziella Filippini; Chiara Falcone; Amerigo Boiardi; Giovanni Broggi; Maria G Bruzzone; Dario Caldiroli; Rita Farina; Mariangela Farinotti; Laura Fariselli; Gaetano Finocchiaro; Sergio Giombini; Bianca Pollo; Mario Savoiardo; Carlo L Solero; Maria G Valsecchi
Journal:  Neuro Oncol       Date:  2007-11-09       Impact factor: 12.300

Review 10.  Chemotherapy of malignant gliomas.

Authors:  Y Ushio; T Hayakawa; H Hasegawa; K Yamada; N Arita
Journal:  Neurosurg Rev       Date:  1984       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.